A phase I dose escalation trial of gemcitabine with radiotherapy for breast cancer in the treatment of unresectable chest wall recurrences

Breast Journal

Volumn 10, Issue 3, 2004, Pages 204-210

  Suh, W Warren ^a   Schott, Anne F ^b   Hayman, James A ^a   Schipper, Matthew J ^c   Shewach, Donna S ^b   Pierce, Lori J ^a,d  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^d NONE   (United States)

Author keywords

Breast cancer; Chest wall failure; Gemcitabine; Mastectomy; Radiotherapy

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; GEMCITABINE; LIVER ENZYME;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER RECURRENCE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DERMATITIS; DRUG EFFECT; DRUG EFFICACY; FATIGUE; HUMAN; IDIOSYNCRATIC DRUG RASH; KAPLAN MEIER METHOD; LIVER DYSFUNCTION; LIVER ENZYME ELEVATION; LYMPH NODE; MASTECTOMY; MAXIMUM TOLERATED DOSE; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; RADIATION INJURY; RASH; SKIN EXFOLIATION; SKIN TOXICITY; THORAX WALL CANCER; THROMBOCYTOPENIA; TREATMENT FAILURE;

ACTUARIAL ANALYSIS; ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RADIATION-SENSITIZING AGENTS; RADIOTHERAPY, ADJUVANT; SURVIVAL ANALYSIS; THORACIC WALL; TIME FACTORS; TREATMENT OUTCOME;

EID: 2642519543     PISSN: 1075122X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1075-122X.2004.21305.x     Document Type: Article

References (21)

1. Deck KB, Kern WH. Local recurrence of breast cancer. Arch Surg 1976;111:323-25.
2. Fisher B, Redmond C, Poisson R, et al. Eight-year results of a randomized clinical trial comparing total mastectomy and lumpectomy with or without radiation in the treatment of breast cancer. N Engl J Med 1989;320:822-28.
3. Crowe JP Jr, Gordon NH, Antunez AR, et al. Local-regional breast cancer recurrence following mastectomy. Arch Surg 1991;126:429-32.
4. Aberizk WJ, Silver B, Henderson K, et al. The use of radiotherapy for treatment of isolated locoregional recurrence of breast carcinoma after mastectomy. Cancer 1986;58:1214-18.
5. Bedwinek JM, Lee J, Fineberg B, et al. Prognostic indicators in patients with isolated local-regional recurrence of breast cancer. Cancer 1981;47:2232-35.
6. Schwaibold F, Fowble BL, Solin LJ, et al. The results of radiation therapy for isolated local regional recurrence after mastectomy. Int J Radiat Oncol Biol Phys 1991;21:299-310.
7. Stadler B, Kogelnik HD. Local control and outcome of patients irradiated for isolated chest wall recurrences of breast cancer. Radiother Oncol 1987;8:105-11.
8. Halverson KJ, Perez CA, Kuske RR, et al. Isolated local-regional recurrence of breast cancer following mastectomy: radiotherapeutic management. Int J Radiat Oncol Biol Phys 1990;19:851-58.
9. Bedwinek JM, Fineberg B, Lee J, et al. Analysis of failures following local treatment of isolated local-regional recurrence of breast cancer. Int J Radiat Oncol Biol Phys 1981;7:581-85.
10. Lund B, Kristjansen PEG, Hansen HH. Clinical and preclinical activity of 2′,2′-difluorodeoxycytidine (gemcitabine). Cancer Treat Rev 1993;19:45-55.
11. Carmichael J, Possinger K, Phillip P, et al. Advanced breast cancer: a phase II trial with gemcitabine. J Clin Oncol 1995;13:2731-36.
12. Shewach DS, Hahn TM, Chang E, et al. Metabolism of 2′,2′ -difluoro-2′-deoxycytidine and radiation sensitization of human colon carcinoma cells. Cancer Res 1994;54:3218-23.
13. McGinn CJ, Shewach DS, Lawrence TS. Radiosensitizing nucleosides. J Natl Cancer Inst 1997;88:1193-203.
14. Robinson WR, Shewach DS. Radiosensitization by gemcitabine in p53 wild-type and mutant MCF-7 breast carcinoma cell lines. Clin Cancer Res 2001;7:2581-89.
15. Abbruzzese JL, Grunewald R, Weeks EA, et al. A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol 1991;9:491-98.
16. Gruenwald R, Kantarjian H, Keating MJ, et al. Pharmacologically directed design of the dose rate and schedule of 2′,2′-difluorodeoxycitidine (gemcitabine) administration in leukemia. Cancer Res 1990;50:6823-26.
17. Lawrence TS, Eisbruch A, Shewach DS. Gemcitabine-mediated radiosensitization. Semin Oncol 1997;24(2 Suppl 7):S7-24-S7-28.
18. Eisbruch A, Shewach DS, Bradford CR, et al. Radiation concurrent with gemcitabine for locally advanced head and neck cancer: a phase I trial and intracellular drug incorporation study. J Clin Oncol 2001;19:792-99.
19. Pierce LJ, Strawderman MH, Douglas KR, et al. Conservative surgery and radiotherapy for early-stage breast cancer using a lung density correction: the University of Michigan experience. Int J Radiat Oncol Biol Phys 1997;39:921-28.
20. Bedwinek J. Natural history and management of isolated local-regional recurrence following mastectomy. Semin Radiat Oncol 1994;4:260-69.
21. McGinn CJ, Zalupski MM, Shureiqi I, et al. Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 2001;19:4202-8.